Announced
Completed
Synopsis
Novo Holdings, Boehringer Ingelheim and Evotec led a $33m Series A round in Centauri Therapeutics, an immunotherapy company, with participation from Wren Capital. “This investment round is testament to the potential of the Alphamer technology and the progress made to date. The funding will underpin the progression of our AMR efforts, enabling us to identify novel antibacterial candidates and deliver improved treatments for life-threatening infections to the clinic. We will continue to engage with high-calibre investors and grow our team to accelerate these capabilities further," Mike Westby, Centauri Therapeutics Chief Scientific Officer.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.